MPH966の新興薬剤に関する洞察と市場予測：2032年

MPH966（Alvelestat、旧名AZD 9668）は、好中球エラスターゼ（NE）を阻害する新規の経口低分子化合物です。この好中球エラスターゼは肺組織を破壊する重要な酵素です。

Alvelestatは現在、米国国立衛生研究所（NIH）のSteve Pavletic博士が主導する第I/II相試験で研究されており、2024年1月までに完了する予定です。

今後数年間で、閉塞性細気管支炎症候群の市場シナリオは、世界中の広範な研究と医療支出の増加により変化します。各社は、病状を治療／改善するための新たなアプローチに焦点を当てた治療法を開発し、課題を評価し、MPH966の優位性に影響を与える可能性のある機会を模索しています。閉塞性細気管支炎症候群に対する他の新興製品がMPH966に厳しい市場競争をもたらすことが予想され、近い将来、後発の新興治療薬が上市されれば、市場に大きな影響を与えるとみられています。

当レポートでは、主要7ヶ国におけるMPH966市場について調査し、市場の概要とともに、2027年～2032年の売上予測データ、競合情勢、および国別動向などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 閉塞性細気管支炎症候群に対するMPH966の概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• その他の開発活動
• 製品概要

第3章 競合情勢（後期段階の新興治療法）

第4章 MPH966市場評価

• 閉塞性細気管支炎症候群に対するMPH966の市場展望
• 主要7ヶ国市場分析
  • 主要7ヶ国における閉塞性細気管支炎症候群に対するMPH966の市場規模
• 国別市場分析
  • 米国
  • ドイツ
  • 英国

第5章 SWOT分析

第6章 アナリストの見解

第7章 付録

第8章 DelveInsightのサービス内容

第9章 免責事項

第10章 DelveInsightについて

第11章 レポート購入オプション

List of Tables

• Table 1: MPH966, Clinical Trial Description, 2023
• Table 2: MPH966, General Description
• Table 3: Competitive Landscape (Emerging Therapies)
• Table 4: MPH966 Market Size in the 7MM, in USD million (2019-2032)
• Table 5: MPH966 Market Size in the US, in USD million (2019-2032)
• Table 6: MPH966 Market Size in Germany, in USD million (2019-2032)
• Table 7: MPH966 Market Size in France, in USD million (2019-2032)
• Table 8: MPH966 Market Size in Italy, in USD million (2019-2032)
• Table 9: MPH966 Market Size in Spain, in USD million (2019-2032)
• Table 10: MPH966 Market Size in the UK, in USD million (2019-2032)
• Table 11: MPH966 Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: MPH966 Market Size in the 7MM, USD million (2019-2032)
• Figure 2: MPH966 Market Size in the United States, USD million (2019-2032)
• Figure 3: MPH966 Market Size in Germany, USD million (2019-2032)
• Figure 4: MPH966 Market Size in France, USD million (2019-2032)
• Figure 5: MPH966 Market Size in Italy, USD million (2019-2032)
• Figure 6: MPH966 Market Size in Spain, USD million (2019-2032)
• Figure 7: MPH966 Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: MPH966 Market Size in Japan, USD million (2019-2032)

“"MPH966 Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about MPH966 for Bronchiolitis Obliterans Syndrome (BOS) in the seven major markets. A detailed picture of the MPH966 for bronchiolitis obliterans syndrome in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the MPH966 for bronchiolitis obliterans syndrome. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the MPH966 market forecast analysis for bronchiolitis obliterans syndrome in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in bronchiolitis obliterans syndrome.

Drug Summary:

MPH966 (Alvelestat, formerly AZD 9668) is a novel, oral-small molecule that inhibits neutrophil elastase (NE). This neutrophil protease is a key enzyme in destroying lung tissue.

Alvelestat is currently being investigated in Phase I/II study, which Dr. Steve Pavletic leads at the National Institutes of Health (NIH) that is anticipated to be completed by January 2024.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the MPH966 description, mechanism of action, dosage and administration, research and development activities in bronchiolitis obliterans syndrome.
• Elaborated details on MPH966 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the MPH966 research and development activities in bronchiolitis obliterans syndrome across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around MPH966.
• The report contains forecasted sales of MPH966 for bronchiolitis obliterans syndrome till 2032.
• Comprehensive coverage of the late-stage emerging therapies for bronchiolitis obliterans syndrome.
• The report also features the SWOT analysis with analyst views for MPH966 in bronchiolitis obliterans syndrome.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

MPH966 Analytical Perspective by DelveInsight

In-depth MPH966 Market Assessment

This report provides a detailed market assessment of MPH966 for bronchiolitis obliterans syndrome in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2027 to 2032.

MPH966 Clinical Assessment

The report provides the clinical trials information of MPH966 for bronchiolitis obliterans syndrome covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for bronchiolitis obliterans syndrome is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence MPH966 dominance.
• Other emerging products for bronchiolitis obliterans syndrome are expected to give tough market competition to MPH966 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of MPH966 in bronchiolitis obliterans syndrome.
• Our in-depth analysis of the forecasted sales data of MPH966 from 2027 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the MPH966 in bronchiolitis obliterans syndrome.

Key Questions:

• What is the product type, route of administration and mechanism of action of MPH966?
• What is the clinical trial status of the study related to MPH966 in bronchiolitis obliterans syndrome and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the MPH966 development?
• What are the key designations that have been granted to MPH966 for bronchiolitis obliterans syndrome?
• What is the forecasted market scenario of MPH966 for bronchiolitis obliterans syndrome?
• What are the forecasted sales of MPH966 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to MPH966 for bronchiolitis obliterans syndrome?
• Which are the late-stage emerging therapies under development for the treatment of bronchiolitis obliterans syndrome?

Table of Contents

1. Report Introduction

2. MPH966 Overview in Bronchiolitis Obliterans Syndrome

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Late-stage Emerging Therapies)

4. MPH966 Market Assessment

• 4.1. Market Outlook of MPH966 in Bronchiolitis Obliterans Syndrome
• 4.2. 7MM Analysis
  • 4.2.1. Market Size of MPH966 in the 7MM for Bronchiolitis Obliterans Syndrome
• 4.3. Country-wise Market Analysis
  • 4.3.1. Market Size of MPH966 in the United States for Bronchiolitis Obliterans Syndrome
  • 4.3.2. Market Size of MPH966 in Germany for Bronchiolitis Obliterans Syndrome
  • 4.3.3. Market Size of MPH966 in France for Bronchiolitis Obliterans Syndrome
  • 4.3.4. Market Size of MPH966 in Italy for Bronchiolitis Obliterans Syndrome
  • 4.3.5. Market Size of MPH966 in Spain for Bronchiolitis Obliterans Syndrome
  • 4.3.6. Market Size of MPH966 in the United Kingdom for Bronchiolitis Obliterans Syndrome
  • 4.3.7. Market Size of MPH966 in Japan for Bronchiolitis Obliterans Syndrome

5. SWOT Analysis

6. Analysts' Views

7. Appendix

• 7.1. Bibliography
• 7.2. Report Methodology

8. DelveInsight Capabilities

9. Disclaimer

10. About DelveInsight

11. Report Purchase Options